Masashi Kanai

7.8k total citations
160 papers, 3.9k citations indexed

About

Masashi Kanai is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Masashi Kanai has authored 160 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 64 papers in Surgery and 55 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Masashi Kanai's work include Cholangiocarcinoma and Gallbladder Cancer Studies (39 papers), Pancreatic and Hepatic Oncology Research (33 papers) and Cancer Genomics and Diagnostics (26 papers). Masashi Kanai is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (39 papers), Pancreatic and Hepatic Oncology Research (33 papers) and Cancer Genomics and Diagnostics (26 papers). Masashi Kanai collaborates with scholars based in Japan, United States and China. Masashi Kanai's co-authors include Shigemi Matsumoto, Tsutomu Chiba, Daoyan Wei, Keping Xie, Y Nimura, Junichi Kamiya, Suyun Huang, Atsushi Imaizumi, Takafumi Nishimura and Yukiko Mori and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Masashi Kanai

151 papers receiving 3.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masashi Kanai Japan	31	1.5k	1.4k	1.2k	847	592	160	3.9k
Shigemi Matsumoto Japan	26	1.6k 1.1×	866 0.6×	557 0.5×	636 0.8×	458 0.8×	136	3.2k
Aaron E. Katz United States	44	558 0.4×	1.4k 1.0×	643 0.5×	3.0k 3.5×	401 0.7×	170	5.1k
Keiji Matsuda Japan	30	1.2k 0.8×	615 0.4×	828 0.7×	535 0.6×	135 0.2×	162	2.8k
Yoshinaga Okugawa Japan	43	2.5k 1.7×	3.5k 2.4×	1.0k 0.9×	939 1.1×	141 0.2×	237	6.9k
Kazuhiro Yanagihara Japan	29	1.2k 0.8×	1.2k 0.8×	350 0.3×	979 1.2×	192 0.3×	116	3.0k
Laurent Guy France	42	820 0.5×	1.5k 1.0×	1.3k 1.1×	1.3k 1.5×	77 0.1×	153	4.5k
Haibo Wang China	27	677 0.5×	1.2k 0.9×	262 0.2×	370 0.4×	95 0.2×	165	2.5k
Takafumi Nishimura Japan	21	639 0.4×	823 0.6×	197 0.2×	269 0.3×	306 0.5×	51	1.8k
E Reed United States	33	2.0k 1.3×	2.5k 1.7×	544 0.5×	811 1.0×	96 0.2×	82	4.7k
Yanhong Gu China	33	1.1k 0.7×	1.5k 1.0×	336 0.3×	504 0.6×	52 0.1×	118	3.2k

Countries citing papers authored by Masashi Kanai

Since Specialization

Citations

This map shows the geographic impact of Masashi Kanai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masashi Kanai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masashi Kanai more than expected).

Fields of papers citing papers by Masashi Kanai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masashi Kanai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masashi Kanai. The network helps show where Masashi Kanai may publish in the future.

Co-authorship network of co-authors of Masashi Kanai

This figure shows the co-authorship network connecting the top 25 collaborators of Masashi Kanai. A scholar is included among the top collaborators of Masashi Kanai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masashi Kanai. Masashi Kanai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kondo, Tomohiro, Osamu Kikuchi, Yoshihiro Yamamoto, et al.. (2024). Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors. The Oncologist. 30(2). 1 indexed citations

Kondo, Tomohiro, Osamu Kikuchi, Yukie Nakai, et al.. (2024). Abstract 4659: A genome-wide CRISPR screen identifies ARID1A as a potential resistance marker of IDH1 inhibitor in IDH1-mutant cholangiocarcinoma cell. Cancer Research. 84(6_Supplement). 4659–4659.

Yamada, Atsushi, et al.. (2024). Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring TFG-MET fusion. International Cancer Conference Journal. 13(3). 199–203. 1 indexed citations

Nakamura, Ikuo, Etsuro Hatano, Hideo Baba, et al.. (2023). Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. Annals of Gastroenterological Surgery. 7(6). 1009–1020. 6 indexed citations

Okuma, Hitomi Sumiyoshi, Kenji Tsuchihashi, Ryunosuke Machida, et al.. (2023). Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial). Clinical Cancer Research. 29(24). 5079–5086. 7 indexed citations

Kondo, Tomohiro, Masashi Kanai, Junichi Matsubara, et al.. (2023). Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study. Medical Oncology. 40(5). 144–144. 1 indexed citations

Seo, Satoru, Etsuro Hatano, Masashi Kanai, et al.. (2022). Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery. Anticancer Research. 42(12). 6127–6134. 2 indexed citations

Kanai, Masashi, Tadayuki Kou, Keitaro Doi, et al.. (2020). Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report. BMC Cancer. 20(1). 1177–1177. 4 indexed citations

Yoshimura, Michio, Ryo Ashida, Yökö Gotö, et al.. (2020). Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Radiation Oncology. 15(1). 264–264. 6 indexed citations

10.

Gotö, Yökö, Akira Nakamura, Ryo Ashida, et al.. (2018). Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiation Oncology. 13(1). 118–118. 31 indexed citations

11.

Masui, Toshihiko, Kyoichi Takaori, Takayuki Anazawa, et al.. (2017). A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement. Anticancer Research. 37(12). 7023–7030. 4 indexed citations

12.

Hasegawa, Suguru, Saori Goto, Takuya Matsumoto, et al.. (2017). A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. Annals of Surgical Oncology. 24(12). 3587–3595. 40 indexed citations

13.

Muto, Manabu, Yu Uneno, Yoshitaka Nishikawa, et al.. (2015). A new approach to collecting biobank and bioinformatics data at Kyoto University Cancer Center. Annals of Oncology. 26. vii90–vii90. 1 indexed citations

14.

Hamamoto, Yasuo, Michitaka Nagase, Shinichi Egawa, et al.. (2015). Prognostic index model for overall survival in advanced unresectable pancreatic cancer from GEST study. Annals of Oncology. 26. vii74–vii74. 1 indexed citations

15.

Kishi, Takahiro, Akira Nakamura, Satoshi Itasaka, et al.. (2015). Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology. 15(6). 694–700. 25 indexed citations

16.

Fujiwara, Yutaka, Shogo Kobayashi, Hiroaki Nagano, et al.. (2015). Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PLoS ONE. 10(12). e0143072–e0143072. 15 indexed citations

17.

Kanai, Masashi, Akira Yoshioka, Shiro Tanaka, et al.. (2010). Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiology. 34(2). 189–193. 30 indexed citations

18.

Kanai, Masashi, Shin‐ya Morita, Shiro Matsumoto, et al.. (2009). A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Annals of Oncology. 20(8). 1397–1401. 18 indexed citations

19.

Kanai, Masashi, Shigemi Matsumoto, Yutaka Shimada, et al.. (2007). Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. International Journal of Clinical Oncology. 12(3). 224–227. 12 indexed citations

20.

Ercolani, Giorgio, Takeshi Sano, Junichi Kamiya, et al.. (1999). Advanced adenosquamous carcinoma of the gallbladder with bilio-biliary fistula: an uncommon case treated by hepatopancreatoduodenectomy.. PubMed. 46(27). 1650–4. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact